InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results
Portfolio Pulse from
InspireMD, Inc. (Nasdaq: NSPR) reported its Q4 and full-year 2024 financial results, highlighting significant progress. The company engaged with the FDA for the CGuard Prime carotid stent system's PMA application, aiming for approval in H1 2025. InspireMD also set quarterly revenue and unit records.
March 12, 2025 | 11:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
InspireMD reported strong Q4 and FY 2024 results, with record revenues and units sold. The company is working with the FDA for CGuard Prime's approval, targeting a US launch in H1 2025.
The financial results show strong performance with record revenues, indicating positive business momentum. The engagement with the FDA for CGuard Prime's approval suggests potential future growth, especially with the anticipated US launch.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100